AngioDynamics Inc (NASDAQ: ANGO) kickstarted fiscal Q1 2025 with a revenue of $67.5 million, reflecting a modest growth of 1.1% year-over-year. The increase was largely driven by strong performance in the MedTech segment, which reported 9% growth spurred by the success of Auryon and AlphaVac products, both of which saw substantial revenue increases. However, the company reported an adjusted EBITDA loss of $200K and a net loss of $12.8 million, signaling ongoing challenges in attaining profitability despite sales growth. Management emphasized continued focus on enhancing operational efficiency and expanding product offerings as pathways toward improving margins and achieving a breakeven cash flow status in the fiscal 2026. Overall, while there are promising growth drivers within the product portfolio, the company still faces significant hurdles in managing costs and achieving sustained profitability.